Gain Therapeutics, Inc.
GANX
$2.12
-$0.05-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 1.82% | -5.42% | -24.17% | -24.68% | 40.16% |
| Gross Profit | -1.82% | 5.42% | 24.17% | 24.68% | -40.16% |
| SG&A Expenses | -8.36% | -10.82% | -10.26% | -16.89% | -2.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.16% | -8.00% | -17.92% | -21.02% | -4.91% |
| Operating Income | 3.16% | 8.00% | 17.92% | 21.02% | 4.91% |
| Income Before Tax | 0.07% | 2.89% | 15.12% | 17.21% | 3.57% |
| Income Tax Expenses | 52.85% | 60.41% | 2,680.47% | 1,226.44% | 648.36% |
| Earnings from Continuing Operations | -1.49% | 1.22% | 9.24% | 13.92% | 1.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.49% | 1.22% | 9.24% | 13.92% | 1.03% |
| EBIT | 3.16% | 8.00% | 17.92% | 21.02% | 4.91% |
| EBITDA | 3.19% | 8.05% | 17.95% | 21.06% | 4.92% |
| EPS Basic | 32.87% | 34.85% | 43.72% | 50.90% | 42.04% |
| Normalized Basic EPS | 34.20% | 36.21% | 47.31% | 52.78% | 43.28% |
| EPS Diluted | 32.87% | 34.85% | 43.72% | 50.90% | 42.04% |
| Normalized Diluted EPS | 34.20% | 36.21% | 47.31% | 52.78% | 43.28% |
| Average Basic Shares Outstanding | 42.35% | 44.20% | 54.59% | 74.48% | 75.84% |
| Average Diluted Shares Outstanding | 42.35% | 44.20% | 54.59% | 74.48% | 75.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |